These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 35549570)
1. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies? Askenase PW J Extracell Vesicles; 2020 Oct; 10(1):e12004. PubMed ID: 33304473 [TBL] [Abstract][Full Text] [Related]
2. Exosome for mRNA delivery: strategies and therapeutic applications. Iqbal Z; Rehman K; Mahmood A; Shabbir M; Liang Y; Duan L; Zeng H J Nanobiotechnology; 2024 Jul; 22(1):395. PubMed ID: 38965553 [TBL] [Abstract][Full Text] [Related]
3. SAR, Molecular Docking and Molecular Dynamic Simulation of Natural Inhibitors against SARS-CoV-2 Mpro Spike Protein. Salamat A; Kosar N; Mohyuddin A; Imran M; Zahid MN; Mahmood T Molecules; 2024 Mar; 29(5):. PubMed ID: 38474656 [TBL] [Abstract][Full Text] [Related]
4. Exosomes: a promising avenue for cancer diagnosis beyond treatment. Wang Z; Wang Q; Qin F; Chen J Front Cell Dev Biol; 2024; 12():1344705. PubMed ID: 38419843 [TBL] [Abstract][Full Text] [Related]
5. mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown! Chavda VP; Jogi G; Dave S; Patel BM; Vineela Nalla L; Koradia K Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992091 [TBL] [Abstract][Full Text] [Related]
14. Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2. Taşlı NP; Gönen ZB; Kırbaş OK; Gökdemir NS; Bozkurt BT; Bayrakcı B; Sağraç D; Taşkan E; Demir S; Ekimci Gürcan N; Bayındır Bilgiç M; Bayrak ÖF; Yetişkin H; Kaplan B; Pavel STI; Dinç G; Serhatlı M; Çakırca G; Eken A; Aslan V; Yay M; Karakukcu M; Unal E; Gül F; Basaran KE; Ozkul Y; Şahin F; Jones OY; Tekin Ş; Özdarendeli A; Cetin M Front Immunol; 2022; 13():824378. PubMed ID: 35401544 [TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627 [TBL] [Abstract][Full Text] [Related]
16. The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients. Chen H; Zhang X; Liu W; Xue M; Liao C; Huang Z; Hu H; Sun B Int Immunopharmacol; 2021 Feb; 91():107325. PubMed ID: 33401205 [TBL] [Abstract][Full Text] [Related]
17. Detection of IgG Antibodies to SARS-CoV-2 and Neutralizing Capabilities Using the Luminex King A; King G; Weiss C; Dunbar S; Das S Methods Mol Biol; 2022; 2511():257-271. PubMed ID: 35838966 [TBL] [Abstract][Full Text] [Related]
18. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection. Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411 [TBL] [Abstract][Full Text] [Related]